GUYER DAVID R 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Jun 4, 2024
Insider Transaction Report
Form 4
GUYER DAVID R
Director
Transactions
- Exercise/Conversion
Common Stock
2024-06-03$3.50/sh+3,250$11,375→ 15,325 total - Sale
Common Stock
2024-06-03$10.30/sh−11,625$119,705→ 3,700 total - Exercise/Conversion
Common Stock
2024-06-03$3.26/sh+6,525$21,272→ 12,075 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-03−6,525→ 13,050 totalExercise: $3.26From: 2024-01-06Exp: 2033-06-19→ Common Stock (6,525 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-03−3,250→ 6,500 totalExercise: $3.50From: 2024-02-23Exp: 2033-06-19→ Common Stock (3,250 underlying)
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.87. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.